当前位置: 首页 > 期刊 > 《中国实用医药》 > 2008年第25期
编号:11667197
支气管哮喘治疗的新进展(2)
http://www.100md.com 2008年9月15日 《中国实用医药》 2008年第25期
     [4] Bisgaard H.Leukotriene modifiers in pediatric asthma management.Pediatrics,2001,107(2):381-390.

    [5] Barnes NC,De Jong B,Miyamoto T.Worldwide clinical experience with the first marketed leukotriene receptor antagonist.Chest,1997,111(2):52-60.

    [6] Donohue JF.Safety and efficacy of Beta agonists.Respir Care,2008,53(5):618-624.

    [7] Humbert M,Garcia G,Chanez P.Targeted immunologic therapies for severe asthma.Presse Med,2008,37(1 Pt 2):173-181.Epub 2007 Nov 5.

    [8] Morokata T,Ida K,Yamada T.CharacterizatiOn 0f YM一90709 as a novel antagonist which inhibits the binding of interleukin一5 to interleukin一5 receptor.Int Immunopharmacol,2002,2(12):1693-1702.

    [9] Hogan SP,et al.Eur J Immunol,1998,28:413-423.

    [10] Wrighton CJ,et al.J Exp Med,1996;183:1013-1022.

    [11] Miller JD,Cox G,Vincic L,et al.A prospective feasibility study of bronchial th1ermoplasty in the human airway.Chest,2005,127:1999-2006.

    [12] Laviolette M,Rubin A,Thomson N,et al.Reduction in mild exacerbation rates and improvement in asthma status following bronchial thermoplasty.Chest,2006,130:109., http://www.100md.com(司津歌 姜雪霏 刘佳丽)
上一页1 2